MSD New Zealand
A research-intensive biopharmaceutical subsidiary operating in New Zealand that conducts clinical research and supplies medicines and vaccines across oncology, vaccines and infectious diseases. Activities include discovery and development of medicines and vaccines, small-molecule process research and scale-up, partnerships and licensing, pharmacovigilance and distribution, sustainability programmes, and health awareness/patient education resources. The organisation participates in public-private collaborations and funds investigator-initiated clinical programmes.
Industries
N/A
Nr. of Employees
small (1-50)
MSD New Zealand
Merck Sharp & Dohme (New Zealand) Limited, Level 3, 123 Carlton Gore Road, Newmarket, Auckland 1023, PO Box 99851, 1149, New Zealand
Products
Prescription medicines and vaccines portfolio (New Zealand)
A local portfolio of prescription medicines and vaccines across therapeutic areas including oncology, infectious diseases, antivirals and antibiotics, supplied for New Zealand patients.
Prescription medicines and vaccines portfolio (New Zealand)
A local portfolio of prescription medicines and vaccines across therapeutic areas including oncology, infectious diseases, antivirals and antibiotics, supplied for New Zealand patients.
Services
Evaluation and collaboration on licensing and partnership opportunities across discovery to clinical-stage programmes.
Receiving and processing of adverse event reports and product complaints via dedicated phone and email channels.
Collaborative research programmes with governments, NGOs and academic partners, including funding support for investigator-initiated studies.
Development and provision of patient-facing educational content, including downloadable booklets and web-based information on disease stages, symptoms, risk factors and treatment pathways.
Evaluation and collaboration on licensing and partnership opportunities across discovery to clinical-stage programmes.
Receiving and processing of adverse event reports and product complaints via dedicated phone and email channels.
Collaborative research programmes with governments, NGOs and academic partners, including funding support for investigator-initiated studies.
Development and provision of patient-facing educational content, including downloadable booklets and web-based information on disease stages, symptoms, risk factors and treatment pathways.
Expertise Areas
- Clinical trial management
- Vaccine development
- Oncology drug development
- Infectious disease research
Key Technologies
- Small-molecule process chemistry
- Vaccine platform development
- Clinical trial design and management systems
- Adverse event reporting systems
News & Updates
Local office purchased certified renewable energy as part of site-level decarbonisation and ESG goals.
Summary letter describing sustainability strategy, access goals, R&D investment and ESG financing; includes global access and sustainability commitments.
Patient-facing resource explaining cancer staging, pathways following an early-stage diagnosis, and benefits versus risks of early-stage cancer treatment; downloadable booklet available.
Overview of key facts about lung cancer including stigma, support needs, risk factors, and advances in research.
Educational content on melanoma incidence, signs (ABCDE rule), risk factors and ways to reduce risk such as sun protection.
Reported exceeding a goal to enable 100 million more people to access its portfolio and increased the ambition to enable 350 million by 2025 (global statement in Impact Report).
Local office purchased certified renewable energy as part of site-level decarbonisation and ESG goals.
Summary letter describing sustainability strategy, access goals, R&D investment and ESG financing; includes global access and sustainability commitments.
Patient-facing resource explaining cancer staging, pathways following an early-stage diagnosis, and benefits versus risks of early-stage cancer treatment; downloadable booklet available.
Overview of key facts about lung cancer including stigma, support needs, risk factors, and advances in research.
Educational content on melanoma incidence, signs (ABCDE rule), risk factors and ways to reduce risk such as sun protection.
Reported exceeding a goal to enable 100 million more people to access its portfolio and increased the ambition to enable 350 million by 2025 (global statement in Impact Report).